Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus

Suhail Ahmed Almani 1, Iqbal Ahmed Memon 1, Tariq Zaffar Shaikh 1, Haji Khan Khoharo 2*, Ikrumuddin Ujjan 3

1 Department of Medicine, Liaquat University of Medical and Health Sciences Jamshoro, Sindh, Pakistan
2 Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad, Sindh, Pakistan
3 Department of Pathology, Liaquat University of Medical and Health Sciences Jamshoro, Sindh, Pakistan

Abstract

Objective(s): Causality of occurrence of metformin-associated lactic acidosis (MALA) is a clinical problem. Currently, there is no drug available to prevent MALA. The present study was conducted to evaluate the protective effect of Berberine (BBR) against MALA in induced diabetic rat model.

Materials and Methods: A sample of 75 healthy male Wistar rats was randomly selected according to inclusion and exclusion criteria. 75 male Wistar rats were randomly divided into a control and 4 experimental groups. Streptozotocin (STZ) in citrate buffer (pH 4.5) at a dose of 45 mg/kg was injected for induction of diabetes mellitus and rats achieving fasting blood glucose >250 mg/dl were included. Blood samples were collected 18 hr after the last dose of metformin and berberine. Ethical approval was taken before the study was conducted. Staistix 10.0 (USA) software was used for data analysis.

Results: Berberine decreased MALA. Metformin, metformin + BBR 50 mg/kg bwt, and metformin + BBR 100 mg/kg bwt showed serum lactate as 1.87 ± 0.4 mmol/L, 1.62 ± 0.44 mmol/L, and 1.47 ± 0.45 mmol/L respectively (P<0.0001). Insulin resistance and liver enzymes were improved in BBR treated rats.

Conclusion: The present study reports berberine protects against MALA in streptozocin-induced diabetes mellitus.

Introduction

Diabetes mellitus (DM) is estimated to reach almost 600 million by the year 2035 as reported by World Health Organization (1, 2). Metformin is a biguanides drug, used as first-line for type 2 diabetics (T2DM). It is preferred as a first line drug because of its mortality and morbidity decreasing potential due to cardiovascular events (3, 4). Except for gastrointestinal side effects, the safety profile of metformin is well established. However, clinicians are scared of one rare side effect of metformin therapy; the lactic acidosis (LA) caused most probably by mitochondrial dysfunction. Causality of occurrence of LA with metformin therapy is debatable. Risk of metformin-associated LA (MALA) ranges from 2 to 9/100 000 patients (5, 6).

However, spontaneous reporting of LA is growing (5-7). MALA carries 50% mortality which is very high (7). While other studies have reported 26 to 30% mortality (5, 7, 8). The present study was conducted to analyze the effects of Berberine (BBR) against MALA.

BBR is a natural herbal agent, which is the active incipient of the Chinese herb Coptis chinensis Franch which has been used since time immemorial. Chemically, BBR is an isoquinoline alkaloid. Its chemical structure is different from existing anti-diabetic drugs such as sulfonylureas, metformin, sitagliptin, etc. BBR has been used as a traditional remedy for gut disorders. As part of folk medicine, the BBR has been used as a remedy for DM since ancient times (9, 10).

In this context, the present experimental study was designed to evaluate and analyze the efficacy of BBR in MALA in a male Wistar albino rat model.

The present study is the first type of its design which was conducted to assess whether BBR is effective against MALA, which is a medical emergency if such effect is proved it may benefit the diabetic community.

Materials and Methods

The present experimental study was conducted at the Animal House of Faculty of Medicine and Allied Medical Sciences (FMAMS), Isra University, Hyderabad, Sindh, Pakistan.
Sindh, Pakistan from January 2016 to July 2016. A sample of 75 healthy male Wistar rats was randomly selected according to inclusion and exclusion criteria. Animals were bought from Jinnah Postgraduate Medical Center (JPMC), belonging to Charles River Breeding Laboratories, Brooklyn, Massachusetts, USA. They were cross bred at the Animal house of the Basic Medical Sciences Institute (BMSI), JPMC, Karachi, Pakistan.

Animal housing

Animals were handled according to the animal ethics guidelines of the National Institute of Health (NIH) and animal ethics committee of the institute. Animals were acclimatized for one week. Stainless steel cages with automatic nozzles were used for housing of rats. Pellet diet and water was available freely. Access to food and water was ad libitum. 12 hr light-dark cycle was maintained with 25±2 °C temperature.

Inclusion criteria

Male Wistar rats of 10 weeks age, healthy, and weighing 150–200 g were included.

Exclusion criteria

Female Wistar rats, diseased, sick, and lazy male Wistar rats were strictly excluded.

Animal groups

75 male Wistar rats were randomly divided into the control and 4 experimental groups;

Group A (n=15): Normal healthy rats taken as controls. 0.9% Normal saline

Group B (n=15): Streptozocin induced Diabetic rats

Group C (n=15): Diabetic rats + Metformin (100 mg/kg bwt) (11) daily for 28 days

Group D (n=15): Diabetic rats + Metformin (100 mg/kg bwt) + BBR (50 mg/kg bwt)12 daily for 28 days

Group E (n=15): Diabetic rats + Metformin (100 mg/kg bwt)11 + BBR (100 mg/kg bwt) daily for 28 days.

Induction of diabetes mellitus

Streptozotocin (STZ) in citrate buffer (pH 4.5) at a dose of 45 mg/kg body weight (mg/kg bwt) was injected subcutaneously to 12 hr fasting rats. 48 hr were lapsed for stabilization of blood glucose. Rats which showed elevated fasting blood glucose (>250 mg/dl) were included (11).

Chemicals

Metformin was purchased from the Merck Pharmaceutical Company. Berberine hydrochloride was purchased through the pharmacy department of the institute. Tweens 80 was used along with sterile water for injection of the prepared formulation.

Blood sampling

Blood samples were collected 18 hr after the last dose of metformin and BBR. Blood was collected by cardiac puncture. Each sample was collected in a gel tube (without anti-coagulant) and incubated for 15 min at room temperature. Disposable syringe (BD, USA) was used for cardiac puncture. Blood was centrifuged at 3000 rpm for 15 min. Clear sera were stored at -20°C for biochemical analysis.

Biochemical testing

Blood glucose- fasting and random, HbA1c, fasting insulin, serum bilirubin, liver enzymes, serum lactate, and serum creatinine were detected on a Roche Biochemical analyzer (Cobas e 411 analyzer, Roche Diagnostics GmbH, Mannheim, Germany). Homeostasis model assessment (HOMA) was calculated as HOMA insulin resistance (HOMA-IR) = fasting insulin × fasting glucose/22.5 (13, 14).

Ethical approval

Ethical approval was taken before the study was conducted. Performa was designed for data collection.

Statistical analysis

Statistix 10.0 (USA) software was used for data analysis. One way analysis of variance with descriptive statistics and post hoc Bonferroni test were used for data analysis. Results were presented as mean± SD. Statistical analysis was performed at 95% confidence interval (P≤0.05).

Results

The present experimental study was conducted with a sample of 75 Wistar male albino rats. Group A comprised of control rats. Experimental groups (streptozocin-treated) included B, C, D, and E. Blood glucose, glycated HbA1c, serum lactate, fasting blood glucose, fasting insulin, and HOMA-IR (%) showed positive results in the BBR treated animals. Serum lactic acid was reduced by co-administration of BBR in metformin-treated animals. Metformin (group C), metformin + BBR 50 mg/kg bwt (group D), and metformin + BBR 100 mg/kg bwt (group E), revealed serum lactate as 1.87±0.4 mmol/l, 1.62±0.44 mmol/l and 1.47±0.45 mmol/l, respectively (Table 1) (P= 0.0001). Fasting glucose, fasting insulin and HOMA-IR model showed amelioration in BBR treated rats. Insulin resistance was decreased in high dose BBR treated rats. Liver aminotransferase (ALT, AST), alkaline phosphatase (ALP), Lactate dehydrogenase (LDH), Y-glutamyl transferase (Y-GT), serum bilirubin, and serum creatinine also revealed statistically significant amelioration in BBR treated animals (Table 2).
Discussion

The present study demonstrates for the first time that BBR protects against MALA. The exact role of metformin in the lactic acidosis is not understood. The Cochrane group (15) comparative outcomes study of metformin intervention versus the conventional approach (COSMIC) study, (16) and the United Kingdom prospective diabetes study (17) have disputed the existence of lactic acidosis in the presence of metformin and hence the term metformin-induced lactic acidosis has subsequently been changed to MALA. Metformin reduces pyruvate dehydrogenase activity and mitochondrial transport of reducing agents, and thus enhances anaerobic metabolism. This shift to anaerobic metabolism, in the presence of reduced insulin, increases production of precursors of the Kreb’s cycle (15-17).

The fasting glucose, fasting insulin, and HOMA-IR model showed improvement with a decrease in insulin resistance by BBR. A significant decrease in liver aminotransferase, ALP, LDH, YGT, and serum bilirubin proves the hepatoprotective effect of BBR.

Anti-diabetic activity of BBR has been suggested by previous studies, (18-20) A clinical study reported BBR exerts glycemic regulatory potential in T2DM. Three months therapy with BBR decreased fasting blood glucose from 11.6 to 6.6 mmol/L, as reported by the previous study (18). A previous study used 0.3-0.5 g of BBR thrice a day and reported a decrease in fasting and random blood glucose by 21% and 27%, respectively (19). Yet another previous study reported total cholesterol reduction by 23%, triglyceride by 40% and fasting blood glucose by 31% with 500 mg of BBR three times a day in T2DM.

MALA is a medical emergency which carries 50% mortality rate, (2, 21) hence there is a need to search for new remedies to overcome the problem. Some of the previous studies concluded that MALA is not life threatening in the long term, (21) while other studies suggested MALA patients must be treated by dialysis to prevent morbidity and mortality (22, 23). However, it is an established fact that MALA is rare but life threatening (24). Within 2 years of clinical use of metformin in the USA, 2-9 cases of MALA per 100,000 were reported with mortality rate as high as 50% (25). Pathophysiology is not understood and remains to be elucidated (26). One suggested mechanism is interference with liver lactate clearance by metformin through inhibition of complex I of the respiratory chain (25, 27). Later on it was reported that lactic acidosis was associated with mitochondrial dysfunctions through inhibition of mitochondrial protein synthesis (28). Thus above scientific investigations and interpretations point towards in-depth studies on the effects of the metformin.

Surely, the present is the first report on the investigation of combined effects of BBR and metformin in Streptozocin-induced diabetes in which the serum lactate was found low in BBR treated rats. Together with the lactic acidosis, it was also thought essential to investigate the other important biochemical parameters to correlate the functioning of the vital organs like liver (liver transaminase) and kidney (serum creatinine) in diabetic rats.

Hence the present study was conducted to analyze the effect of Metformin and BBR combination on different biochemical parameters with special reference to serum lactate. Diabetic rats were used in

Table 1. Blood glucose, serum lactate, and insulin resistance in controls and experimental rats (n=75)

| Parameters          | Group A Controls | Group B Diabetics | Group C Diabetics+ Met BBR (low dose) | Group D Diabetics+ Met+ BBR (low dose) | Group E Diabetics+ Met+ BBR (high dose) | P-value |
|---------------------|------------------|-------------------|--------------------------------------|----------------------------------------|-----------------------------------------|---------|
| Blood glucose (R) (mg/dl) | 348±15.5        | 348±15.5        | 290.4±7.8                            | 244.1±6.7                              | 209.3±7.6                               | 0.0001  |
| Glycated HbA1 (%)   | 4.9±0.8          | 11.9±1.2         | 11.0±1.2                             | 10.3±1.6                               | 10.2±1.7                                | 0.001   |
| Serum lactate (mmol/L) | 0.6±0.14         | 1.2±0.44         | 1.87±0.4                            | 1.62±0.4                              | 1.47±0.4                                | 0.049   |
| Fasting glucose (mg/dl) | 106.0±12.4      | 190.9±35.5       | 171.7±24.9                           | 160.7±24.2                             | 146.5±35.4                              | 0.019   |
| Fasting Insulin (µU/ml) | 19.9±4.4         | 32.0±1.9         | 30.1±2.6                             | 26.7±2.8                               | 22.3±9.0                                | 0.0001  |
| HOMA-IR (%)         | 2.1±0.3          | 4.7±0.4          | 4.4±0.8                              | 3.8±1.2                                | 3.2±1.4                                 | 0.035   |

† P < 0.05; Met: metformin; BBR: Berberine

Table 2. Liver enzymes, serum bilirubin, and serum creatinine in controls and experimental rats (n=75)

| Parameters          | Group A Controls | Group B Diabetics | Group C Diabetics+ Met BBR (low dose) | Group D Diabetics+ Met+ BBR (low dose) | Group E Diabetics+ Met+ BBR (high dose) | P-value |
|---------------------|------------------|-------------------|--------------------------------------|----------------------------------------|-----------------------------------------|---------|
| ALT (U/L)           | 34.8±7.8         | 68.8±15.4        | 65.6±12.5                            | 58.9±9.1                               | 52.1±6.7                                | 0.0001  |
| AST (U/L)           | 27.5±4.1         | 50.3±11.5        | 38.1±12.6                            | 33.2±5.0                               | 31.8±6.6                                | 0.009   |
| ALP (U/L)           | 75.9±17.0        | 144.9±35.0       | 114.7±47.0                           | 105.6±44.6                             | 93.3±33.8                               | 0.029   |
| LDH (U/L)           | 111.3±18.2       | 173.1±26.9       | 154.7±35.1                           | 133.7±28.4                             | 121.5±7.8                               | 0.001   |
| GGT (U/L)           | 35.5±6.3         | 78.9±5.3         | 57.7±22.9                            | 55.3±22.1                              | 46.2±20.0                               | 0.029   |
| S. bilirubin (mg/dl) | 0.6±0.1          | 1.5±0.2          | 1.4±0.3                              | 1.3±0.4                                | 1.2±0.3                                 | 0.001   |
| S. creatinine (mg/dl) | 0.8±0.1          | 1.4±0.3          | 1.1±0.2                              | 1.0±0.3                                | 0.9±0.2                                 | 0.001   |

† P < 0.05; Met: metformin; BBR: Berberine
We are thankful to the staff of the animal house and clinical pathological laboratory of the Basic Medical Sciences Institute (BMSI), JPMC, Karachi, Pakistan for their help in the completion of this project.

References
1. Zafar J, Nadeem D, Khan SA, Jawad Abbasi MM, Aziz F, Saeed S. Prevalence of diabetes and its correlates in urban population of Pakistan: A Cross-sectional survey. J Pak Med Assoc 2016; 66:922-927.
2. Lepeley M, Gai J, Yahiaoui N, Chanoine S, Vilierr C. Lactic acidosis in diabetic population: is metformin implicated? results of a matched case-control study performed on the Type 2 diabetes population of grenoble hospital university. J Diabet Res 2016; 2106: 3545914.
3. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: a patient centered approach position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetol 2012; 55:1577–1596.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 2012; 281: 2005–2012.
5. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Safety 2010; 33:727–740.
6. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other anti-diabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabet Care 2008; 31:2086–2091.
7. Lalau JD, Race JM. Lactic acidosis in metformin treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 1999; 20:377–384.
8. Vecchio S, Protti A. Metformin-induced lactic acidosis: no one left behind. Critical Care 2011; 15:1- 107.
9. Chen L, Guo W, Zhang S, Lu W, Liao S, Li Y. Berberine prevents high glucose-induced cell viability inhibition and apoptosis in podocytes. Int J Clin Exp Med 2016; 9:5942-5950.
10. Ni XY. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 1988; 8:711–713.
11. Patel MI, Makhiya SU. Effects of linezolid and metformin combination on vital biochemical functions with special reference to lactic acidosis in streptozotocin induced diabetic rats. Res J Pharm Biol Chem Sci 2013; 4:1278-1288.
12. Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, et al. Effect of berberine on promoting the excretion of...
cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med 2015; 13:278.
13. Manning PJ, Sutherland WH, Walker RJ. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabet Care 2004; 27:2166–2171.
14. Tripathi H. Long-term preservation of donor corneas in glycerol for keratoplasty: exploring new protocols. Br J Ophthalmol 2011; 100:284–90.
15. Salpeter S, Greyber E, Pasternak G. Risk of fatal and non fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4:CD002967.
16. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach: the COSMIC Approach study. Diabet Care 2005; 28:539–543.
17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352:854–865.
18. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008; 294:E148–E156.
19. Xie P, Zhou H, Gao Y. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]. Chin J Clin Healthcare 2005; 8:402–403.
20. Wei J, Wu J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine. Zhong Xi Yi Jie He Ganbing Za Zhi 2004; 14:334–336.
21. Lalau JD, Race JM. Lactic acidosis in metformin treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 1999; 20:377–384.
22. Guariiguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabet Res Clin Prac 2013; 103:137–149.
23. Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol 2011; 74:191-196.
24. Biradar V, Moran JL, Peake SL, Peter JV. Metformin associated lactic acidosis (MALA): clinical profile and outcomes in patients admitted to the intensive care unit. Crit Care Resusc 2010; 12:191–195.
25. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4:CD002967.
26. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetic drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabet Care 2008; 31:2086–2091.
27. Wheaton WW, Weinberg SE, Hamaanaka RB, Soberanes S, Sullivan IB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 2014; 3:e02242.
28. Erejuwa OO, Amrah S, Sulaiman SA, Wahab MS, Salam SK, Salleh MS, et al. Antioxidant protective effect of glibenclamide and metformin in combination with honey in pancreas of streptozotocin-induced diabetic rats. Int J Biol Sci 2011; 7:244–252.
29. Chowdhury TA, Wright R, Yaqub M. Using metformin in the presence of renal disease. Br Med J 2015; 350:h1758.
30. Calabrese AT, Coley KC, Da Pos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162:434–437.
31. Ehrlich DT, Mc Alister FA, Blackburn DR. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br Med J 2007; 335:497–501.
32. Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother 2012; 13:1–8.
33. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabet Obes Metabol 2010; 12:1079–1083.
34. Cayley Jr WE. Does metformin increase the risk of fatal or nonfatal lactic acidosis? Am Family Phys 2010; 82:1068–1070.